Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (151-160 of 760) with videos related to

Pageof 76
Sort By:
Expert Review of Cardiovascular Therapy|July 1, 2011
Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitusDominick J Angiolillo, Marco Roffi, Antonio Fernandez-Ortiz
Expert Review of Cardiovascular Therapy|April 22, 2009
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary interventionPiera Capranzano, Jose Luis Ferreiro, Dominick J Angiolillo
Expert Review of Cardiovascular Therapy|October 10, 2009
Cangrelor: a review on its mechanism of action and clinical developmentJosé Luis Ferreiro, Masafumi Ueno, Dominick J Angiolillo
Thrombosis and Haemostasis|March 19, 2024
The Lipid-Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet ReactivityLuis Ortega-Paz, Francesco Franchi, Dominick J Angiolillo
European Heart Journal. Cardiovascular Pharmacotherapy|July 20, 2025
Reply: Sex-Related Variations in Platelet ReactivityMattia Galli, Dominick J Angiolillo, Fabio M Pulcinelli
European Heart Journal|September 7, 2011
Current concepts on coronary revascularization in diabetic patientsMarco Roffi, Dominick J Angiolillo, A Pieter Kappetein
Future Cardiology|June 2, 2011
Antiplatelet drug therapy: role of pharmacodynamic and genetic testingAntonio Tello-Montoliu, Masafumi Ueno, Dominick J Angiolillo
European Heart Journal. Cardiovascular Pharmacotherapy|February 2, 2022
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19Luis Ortega-Paz, Mattia Galli, Dominick J Angiolillo
Expert Opinion on Investigational Drugs|October 29, 2010
Inhibiting PAR-1 in the prevention and treatment of atherothrombotic eventsSalvatore Davide Tomasello, Dominick J Angiolillo, Shinya Goto
Journal of Cardiovascular Development and Disease|October 26, 2022
P2Y<sub>12</sub> Inhibitor Monotherapy after Percutaneous Coronary InterventionXuan Zhou, Dominick J Angiolillo, Luis Ortega-Paz
Pageof 76

Showing results (151-160 of 760) with videos related to

Sort By:
Pageof 76
Expert Review of Cardiovascular Therapy|July 1, 2011
Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitusDominick J Angiolillo, Marco Roffi, Antonio Fernandez-Ortiz
Expert Review of Cardiovascular Therapy|April 22, 2009
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary interventionPiera Capranzano, Jose Luis Ferreiro, Dominick J Angiolillo
Expert Review of Cardiovascular Therapy|October 10, 2009
Cangrelor: a review on its mechanism of action and clinical developmentJosé Luis Ferreiro, Masafumi Ueno, Dominick J Angiolillo
Thrombosis and Haemostasis|March 19, 2024
The Lipid-Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet ReactivityLuis Ortega-Paz, Francesco Franchi, Dominick J Angiolillo
European Heart Journal. Cardiovascular Pharmacotherapy|July 20, 2025
Reply: Sex-Related Variations in Platelet ReactivityMattia Galli, Dominick J Angiolillo, Fabio M Pulcinelli
European Heart Journal|September 7, 2011
Current concepts on coronary revascularization in diabetic patientsMarco Roffi, Dominick J Angiolillo, A Pieter Kappetein
Future Cardiology|June 2, 2011
Antiplatelet drug therapy: role of pharmacodynamic and genetic testingAntonio Tello-Montoliu, Masafumi Ueno, Dominick J Angiolillo
European Heart Journal. Cardiovascular Pharmacotherapy|February 2, 2022
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19Luis Ortega-Paz, Mattia Galli, Dominick J Angiolillo
Expert Opinion on Investigational Drugs|October 29, 2010
Inhibiting PAR-1 in the prevention and treatment of atherothrombotic eventsSalvatore Davide Tomasello, Dominick J Angiolillo, Shinya Goto
Journal of Cardiovascular Development and Disease|October 26, 2022
P2Y<sub>12</sub> Inhibitor Monotherapy after Percutaneous Coronary InterventionXuan Zhou, Dominick J Angiolillo, Luis Ortega-Paz
Pageof 76